MedTrace Logo

Evaluating Collagen Cross-Linking (CCL) Treatment in Norway

NCT00435799 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-06-10

No results posted yet for this study

Summary

The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.

Conditions

  • Keratoconus

Interventions

PROCEDURE

corneal cross-linking (CCL)

DRUG

Riboflavin/dextran eyedrops

DEVICE

UV-X system

Sponsors & Collaborators

  • Ullevaal University Hospital

    lead OTHER

Principal Investigators

  • Aleksandar Stojanovic, MD · Eye dpt, University Hospital of North Norway

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-01-31
Completion
2010-01-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435799 on ClinicalTrials.gov